Comparative Pharmacology
Head-to-head clinical analysis: DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM versus SCANLUX 300.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM versus SCANLUX 300.
DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM vs SCANLUX-300
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Radiopaque contrast agent that attenuates X-rays, providing visualization of vascular and urinary structures. It is a high-osmolality ionic dimer that distributes in extracellular fluid and is excreted renally.
SCANLUX-300 (gadoxetate disodium) is a hepatobiliary MRI contrast agent that shortens T1 relaxation time, enhancing signal intensity in tissues. It is taken up by hepatocytes via OATP1B1/1B3 transporters and excreted into bile via MRP2, allowing both dynamic and hepatobiliary phase imaging.
Intra-arterial or intravenous administration; adult dose varies by procedure: for intravenous urography, 50-100 mL of 60% solution; for CT enhancement, 100-150 mL of 60% solution; maximum total dose 4.2 g iodine/kg body weight.
30 mg/m² IV over 1 hour every 4 weeks.
None Documented
None Documented
1-2 hours in normal renal function; prolonged in renal impairment (up to 20-30 hours in severe impairment)
Terminal elimination half-life is 3.5 hours (range 2.8–4.5 h); may be prolonged in hepatic impairment (up to 7 h).
Renal: >95% unchanged via glomerular filtration; biliary/fecal: <5%
Renal excretion of unchanged drug accounts for approximately 30% of the administered dose; fecal/biliary elimination accounts for about 60% (via hepatobiliary secretion into feces); minimal excretion via other routes.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent